197 related articles for article (PubMed ID: 24117833)
1. BRAF mutation in 'sarcomas': a possible method to detect de-differentiated melanomas.
Cipriani NA; Letovanec I; Hornicek FJ; Mullen JT; Duan Z; Borger DR; Nielsen GP
Histopathology; 2014 Apr; 64(5):639-46. PubMed ID: 24117833
[TBL] [Abstract][Full Text] [Related]
2. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.
Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T
Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190
[TBL] [Abstract][Full Text] [Related]
4. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
7. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
8. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
9. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M
Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
11. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.
Thiel A; Moza M; Kytölä S; Orpana A; Jahkola T; Hernberg M; Virolainen S; Ristimäki A
Hum Pathol; 2015 Feb; 46(2):169-75. PubMed ID: 25442222
[TBL] [Abstract][Full Text] [Related]
12. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
13. Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma.
Aksenenko MB; Kirichenko AK; Ruksha TG
Pathol Res Pract; 2015 Jul; 211(7):521-7. PubMed ID: 25888143
[TBL] [Abstract][Full Text] [Related]
14. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
15. Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma.
Hookim K; Roh MH; Willman J; Placido J; Weigelin HC; Fields KL; Pang J; Betz BL; Knoepp SM
Cancer Cytopathol; 2012 Feb; 120(1):52-61. PubMed ID: 21793228
[TBL] [Abstract][Full Text] [Related]
16. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
Liu H; Li Z; Wang Y; Feng Q; Si L; Cui C; Guo J; Xue W
Pathol Int; 2014 Dec; 64(12):601-6. PubMed ID: 25359093
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of MiTF staining in undifferentiated pleomorphic sarcoma: caution in the use of melanocytic markers in sarcoma.
Choy B; Hyjek E; Montag AG; Pytel P; Haydon R; Luu HH; Zhen CJ; Long BC; Kadri S; Segal JP; Furtado LV; Cipriani NA
Histopathology; 2017 Apr; 70(5):734-745. PubMed ID: 27926791
[TBL] [Abstract][Full Text] [Related]
19. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
[TBL] [Abstract][Full Text] [Related]
20. Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma.
Yang L; Chen Y; Cui T; Knösel T; Zhang Q; Geier C; Katenkamp D; Petersen I
Hum Pathol; 2012 Sep; 43(9):1463-70. PubMed ID: 22406360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]